home contact company.overview news sitemap print
NMI TT GmbH
page: 2 of 10 | items: 4 to 6 | previous | next
6th Global Reverse Phase Protein Array Workshop
Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for treatment of Fragile X Syndrome
Product Launch: new Cav1.2 cell line
Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension.
topNMI TT a business unit of NMI